Rep. Maria Elvira Salazar Sells Off Shares of Biogen Inc. (NASDAQ:BIIB)

Representative Maria Elvira Salazar (Republican-Florida) recently sold shares of Biogen Inc. (NASDAQ:BIIB). In a filing disclosed on July 07th, the Representative disclosed that they had sold between $15,001 and $50,000 in Biogen stock on June 2nd. The trade occurred in the Representative’s “UBS BROKERAGE ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Voyager Technologies (NYSE:VOYG) on 6/15/2026.
• Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 6/4/2026.
• Purchased $15,001 – $50,000 in shares of Brookfield Renewable Partners (NYSE:BEP) on 6/4/2026.
• Purchased $1,001 – $15,000 in shares of Brookfield Renewable Partners (NYSE:BEP) on 6/4/2026.
• Purchased $1,001 – $15,000 in shares of Brookfield Renewable Partners (NYSE:BEP) on 6/3/2026.
• Purchased $1,001 – $15,000 in shares of Brookfield Renewable Partners (NYSE:BEP) on 6/2/2026.
• Purchased $15,001 – $50,000 in shares of Salesforce (NYSE:CRM) on 6/2/2026.
• Purchased $1,001 – $15,000 in shares of Brookfield Renewable Partners (NYSE:BEP) on 5/29/2026.
• Purchased $15,001 – $50,000 in shares of International Business Machines (NYSE:IBM) on 5/21/2026.
• Purchased $15,001 – $50,000 in shares of Datadog (NASDAQ:DDOG) on 5/19/2026.

Biogen Price Performance

Biogen stock opened at $199.15 on Monday. The stock’s fifty day moving average price is $198.25 and its two-hundred day moving average price is $188.16. The firm has a market cap of $29.40 billion, a PE ratio of 21.37 and a beta of 0.16. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.06 and a quick ratio of 2.41. Biogen Inc. has a one year low of $121.05 and a one year high of $219.72.

Biogen (NASDAQ:BIIB) last released its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.95 by $0.62. The company had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.Biogen’s quarterly revenue was up 1.9% on a year-over-year basis. During the same period in the prior year, the firm posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, research analysts expect that Biogen Inc. will post 13.77 EPS for the current fiscal year.

Hedge Funds Weigh In On Biogen

Several institutional investors and hedge funds have recently added to or reduced their stakes in BIIB. Reflection Asset Management acquired a new position in shares of Biogen during the fourth quarter worth $25,000. WPG Advisers LLC increased its holdings in Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 117 shares in the last quarter. First Horizon Corp bought a new position in Biogen in the fourth quarter valued at about $30,000. Root Financial Partners LLC raised its position in Biogen by 198.4% in the fourth quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 123 shares during the last quarter. Finally, MV Capital Management Inc. acquired a new stake in shares of Biogen during the fourth quarter valued at about $34,000. Institutional investors own 87.93% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on BIIB. Citigroup raised their target price on shares of Biogen from $190.00 to $200.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Sanford C. Bernstein cut their price target on shares of Biogen from $201.00 to $200.00 in a report on Thursday, April 30th. Weiss Ratings upgraded shares of Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 1st. Morgan Stanley lowered their price objective on shares of Biogen from $224.00 to $222.00 and set an “equal weight” rating for the company in a research report on Wednesday. Finally, Oppenheimer upped their target price on Biogen from $275.00 to $300.00 and gave the stock an “outperform” rating in a research note on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $219.85.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.